About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a company based in Pasadena (United States) founded in 1989 was acquired by Regal Rexnord in November 2021. It operates as a HealthTech. Arrowhead Pharmaceuticals has raised $110.98 million across 13 funding rounds from investors including Silence Therapeutics, Orbimed and Regal Rexnord. The company has 609 employees as of September 30, 2024. Arrowhead Pharmaceuticals offers products and services including Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE. Arrowhead Pharmaceuticals operates in a competitive market with competitors including Merck, AbbVie, Lilly, Biogen and Roche, among others.
- Headquarter Pasadena, United States
- Employees 609 as on 30 Sep, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Arrowhead Pharmaceuticals, Inc.
-
Annual Revenue
$3.55 M (USD)-98.52as on Sep 30, 2024
-
Net Profit
-$599.49 M (USD)-192.04as on Sep 30, 2024
-
EBITDA
-$582.49 M (USD)-202.58as on Sep 30, 2024
-
Total Equity Funding
$110.98 M (USD)
in 13 rounds
-
Latest Funding Round
$7.2 M (USD), Post-IPO
Dec 11, 2017
-
Investors
Silence Therapeutics
& 6 more
-
Employee Count
609
as on Sep 30, 2024
-
Acquired by
Regal Rexnord
(Nov 24, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol ARWR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals offers a comprehensive portfolio of products and services, including Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE.
Developed to reduce triglycerides in severe hypertriglyceridemia patients.
Designed to lower LDL in dyslipidemia treatment cases.
Created for treating inflammatory pulmonary diseases effectively.
People of Arrowhead Pharmaceuticals
Unlock access to complete
Leadership Team
35 people
Senior Team
19 people
Software Development Team
18 people
Operations Team
11 people
Data Analysis and Operations Team
9 people
Scientist Team
7 people
Finance and Accounting
6 people
Human Resources and Administration
4 people
Unlock access to complete
Funding Insights of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has successfully raised a total of $110.98M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $7.2 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Silence Therapeutics, Orbimed and Regal Rexnord.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are facilitated by Amgen-backed entity.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Arrowhead Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arrowhead Pharmaceuticals
Investment portfolio details for Arrowhead Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arrowhead Pharmaceuticals
Detailed financials for Arrowhead Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arrowhead Pharmaceuticals Comparisons
Peer comparison for Arrowhead Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Biogen and Roche, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
|
| Locked | Locked | Locked |
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
Detailed competitors of Arrowhead Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arrowhead Pharmaceuticals
Complete news archive for Arrowhead Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals was founded in 1989 and raised its 1st funding round 20 years after it was founded.
Arrowhead Pharmaceuticals is headquartered in Pasadena, United States. It is registered at Pasadena, California, United States.
Christopher Anzalone is the current CEO of Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals is a funded company, having raised a total of $110.98M across 13 funding rounds to date.
As of Sep 30, 2024, the latest employee count at Arrowhead Pharmaceuticals is 609.
Annual revenue of Arrowhead Pharmaceuticals is $3.55M as on Sep 30, 2024.
Arrowhead Pharmaceuticals is engaged in the development of innovative therapeutics using RNA interference (RNAi) technology. The company targets genes causing diseases in areas such as cardiometabolic disorders, severe hypertriglyceridemia, dyslipidemia, cardiovascular disease, and pulmonary inflammatory diseases. Solutions are built on the proprietary TRiM platform, which leverages natural pathways to silence disease-causing genes. Clinical trials are conducted across multiple phases to address significant unmet medical needs. The portfolio includes drug candidates like Plozasiran, Zodasiran, and ARO-RAGE, aimed at diverse therapeutic areas. Operations span various global locations to support research and development efforts.
Arrowhead Pharmaceuticals's top competitors include Merck, Roivant Sciences and Amgen.
Arrowhead Pharmaceuticals offers Plozasiran (ARO-APOC3), Zodasiran (ARO-ANG3), and ARO-RAGE.
Yes, Arrowhead Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol ARWR.
Arrowhead Pharmaceuticals has 7 investors. Key investors include Silence Therapeutics, Orbimed, Regal Rexnord, RTW Investments, and RA Capital.
The ticker symbol of Arrowhead Pharmaceuticals is ARWR on NASDAQ.